| pubmed-article:19228726 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19228726 | lifeskim:mentions | umls-concept:C0014239 | lld:lifeskim |
| pubmed-article:19228726 | lifeskim:mentions | umls-concept:C0149784 | lld:lifeskim |
| pubmed-article:19228726 | lifeskim:mentions | umls-concept:C0815000 | lld:lifeskim |
| pubmed-article:19228726 | lifeskim:mentions | umls-concept:C0060197 | lld:lifeskim |
| pubmed-article:19228726 | lifeskim:mentions | umls-concept:C1176309 | lld:lifeskim |
| pubmed-article:19228726 | lifeskim:mentions | umls-concept:C1527144 | lld:lifeskim |
| pubmed-article:19228726 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:19228726 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
| pubmed-article:19228726 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:19228726 | pubmed:dateCreated | 2009-2-20 | lld:pubmed |
| pubmed-article:19228726 | pubmed:abstractText | The proteasome inhibitor bortezomib inhibited cell growth and angiogenesis in neuroblastoma. Bortezomib has been shown to induce synergistic activity when combined with other antineoplastic agents. Here we have investigated the antitumor activity of bortezomib in combination with fenretinide, a synthetic retinoid, against neuroblastoma cells. | lld:pubmed |
| pubmed-article:19228726 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19228726 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19228726 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19228726 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19228726 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19228726 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19228726 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19228726 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19228726 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:19228726 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:RibattiDomeni... | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:CarosioRobert... | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:PistoiaVitoV | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:GaliettaLuis... | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:NicoBeatriceB | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:PezzoloAnnali... | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:CilliMicheleM | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:PastorinoFabi... | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:BrignoleChiar... | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:PonzoniMircoM | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:PagnanGabriel... | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:MarimpietriDa... | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:Di... | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:PiccardiFeder... | lld:pubmed |
| pubmed-article:19228726 | pubmed:author | pubmed-author:LoiMonicaM | lld:pubmed |
| pubmed-article:19228726 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19228726 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:19228726 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:19228726 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19228726 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19228726 | pubmed:pagination | 1199-209 | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:meshHeading | pubmed-meshheading:19228726... | lld:pubmed |
| pubmed-article:19228726 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19228726 | pubmed:articleTitle | The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response. | lld:pubmed |
| pubmed-article:19228726 | pubmed:affiliation | Laboratory of Oncology, G. Gaslini Children's Hospital, Genoa, Italy. gabriellapagnan@ospedale-gaslini.ge | lld:pubmed |
| pubmed-article:19228726 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19228726 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19228726 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19228726 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19228726 | lld:pubmed |
